A Phase 2 interventional study of Ixekizumab and Placebo in Psoriasis, sponsored by Eli Lilly and Company. Completed at 34 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-24.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.
Among the 22 studies testing ixekizumab in Psoriasis, this one is the 13th largest by enrollment, is the only one that started in 2010, is the only one in phase 2, and was the 1st registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
Singapore General Hospital · Sites in Singapore
Ages 22–90
University of California, San Francisco · Sites in United States
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University
Ages 70+
By country, each count listing its studies:
ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 142 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 156 across the 22 interventional studies. Of the 17 that completed or were terminated, 16 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 6 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
36 studies in Psoriasis by Eli Lilly and Company: 1 open now, 1 under way, none of them phase 3. Of 35 finished, 28 (80%) have results posted.
Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 21st largest by enrollment, is the only one that started in 2010, is one of 9 in phase 2, and was the 2nd registered.
Eli Lilly and Company’s Psoriasis studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing ixekizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 36 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose for this study is to help answer the following research questions
The study is a Phase 2 study with 3 parts. Part A is a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging design, Part B is an optional, open label extension design and Part C is an additional optional extension period with an open-label design(up to approximately 104 weeks). Approximately 125 participants will be randomized to 1 of 4 ixekizumab groups or to placebo (approximately 25 participants per group) in Part A. Participants will be evaluated for treatment efficacy and the primary endpoint will be evaluated at week 12. Between week 20 and week 32, participants with a less than 75% improvement in their Psoriasis Area and Severity Index (PASI) score compared to baseline will be eligible to begin Part B. Participants in Part B will receive subcutaneous (SC) injections of ixekizumab 120 milligrams (mg) every 4 weeks through week 236. Subsequent to an amendment on May 2012, administration changed to 80 mg every 4 weeks through Week 236. Participants in Part C may receive SC injections of ixekizumab 80 mg every 4 weeks for up to an additional 104 weeks through approximately week 340. Participants who complete Part A, Part B, and Part C will have a total study participation of approximately 344 weeks.
Inclusion Criteria Common to Both Part A:
Inclusion Criterion Specific to Part B
Inclusion Criterion Specific to Part C
Exclusion Criteria Common to Part A, B and C:
Exclusion Criteria Specific to B:
Exclusion Criteria Specific to C:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: 10 milligrams (mg) ixekizumab given subcutaneous (SC) on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations. Part B: (optional) 120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236. Part C: (optional) 80 mg ixekizumab given SC Q4W through approximately week 344.
Biological: Ixekizumab
Part A: 25 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations. Part B: (optional) 120 mg ixekizumab given SC (Q4W). Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236. Part C: (optional) 80 mg ixekizumab given SC Q4W through approximately week 344.
Biological: Ixekizumab
Part A: 75 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations. Part B: (optional) 120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236. Part C: (optional) 80 mg ixekizumab given SC Q4W through approximately week 344.
Biological: Ixekizumab
Part A: 150 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations. Part B: (optional) Administered 120 mg ixekizumab SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236. Part C: (optional) 80 mg ixekizumab given SC Q4W through approximately week 344.
Biological: Ixekizumab
Part A: Placebo given on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations. Part B: (optional) 120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236. Part C: (optional) 80 mg ixekizumab given SC Q4W through approximately week 344.
Biological: Ixekizumab · Drug: Placebo
Part B: (optional) 120 mg ixekizumab given SC every 4 weeks. Subsequent to an amendment on May 2012, administration changed to 80 mg every 4 weeks through Week 236. Part C: (optional) 80 mg ixekizumab given SC every 4 weeks through approximately week 344.
Biological: Ixekizumab
Part B: (optional) Subsequent to an amendment on May 2012, administration changed to 80 mg ixekizumab Q4W through Week 236. Part C: (optional) 80 mg ixekizumab given SC every 4 weeks through approximately week 344.
Biological: Ixekizumab
Administered subcutaneously
Also known as: LY2439821
Administered subcutaneously
Percentage of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement
PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no psoriasis) to 72 (the most severe disease).Participants achieving PASI 75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.
Time frame: Week 12
Percentage of PASI Improvement From Baseline to 12 Week Endpoint
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no psoriasis) to 72 (the most severe disease). Least squares (LS) mean values were calculated using mixed model repeated measures (MMRM) and controlled for baseline as a covariate, visit, treatment and visit by treatment interaction as fixed effects, with variance-covariance structure set to unstructured.
Time frame: Baseline to Week 12
Percentage of Participants With a Static Physician's Global Assessment (sPGA) Score of Cleared (0) or Minimal (1) With at Least a 2 Point Improvement" at Week 12
The sPGA of psoriasis is scored on a 6-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 6 point severity scale (0 \[clear\] to 5 \[severe\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the sPGA score and category (0=clear; 1=minimal; 2=mild; 3=moderate; 4=marked; 5 = severe). As defined by protocol, a responder is a participant who has a post-baseline sPGA score of '0' or a post-baseline score of '1' with at least a 2 point improvement from baseline.
Time frame: Week 12
Number of Participants With Treatment Emergent Adverse Events Up to 20 Weeks
Treatment-emergent adverse events (TEAEs) are events which were not present at baseline or pre-existing conditions at baseline that worsened in severity following the start of treatment. A summary of other non-serious Adverse Events (AEs), and all Serious Adverse Events (SAE's), regardless of causality, is located in the Reported Adverse Events section.
Time frame: Baseline Up to 20 Weeks
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Score at Week 16
The HADS is a 14-item, participant self-reported scale that consists of an anxiety scale and a depression scale, each with 7 items. Items are rated on a 4-point Likert-type scale ranging from 0 (low level of anxiety or depression) to 3 (high level of anxiety or depression). Each subscale score ranges from 0 to 21 with higher scores indicating greater symptom severity. The classification is defined: 0-7 normal, 8-10 Borderline, 11-21 Abnormal. LS mean was calculated using the analysis of covariance (ANCOVA) model including treatment as fixed effect and baseline as covariate.
Time frame: Baseline, Week 16
Change From Baseline in 16-Item Quick Inventory of Depressive Symptoms- Self Rated (QIDS-SR16) Total Score at Week 16
The QIDS-SR16 is a self-administered, 16-item instrument in which a participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 (best) to 3 (worst). The 16 items are scored to give 9 individual depression domains (sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance \[initial, middle and late insomnia or hypersomnia\], decrease/increase in appetite/weight, and psychomotor agitation/retardation), which are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. The LS Mean (no multiplicity adjustments) are presented for each treatment versus placebo comparison at each visit and use an analysis of covariance (ANCOVA) model including baseline as a covariate and treatment as fixed effect in the model.
Time frame: Baseline, Week 16
Change From Baseline in Patient Global Assessment (PatGA) at Week 12
The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis "today" by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been). The LS Mean (no multiplicity adjustments) are presented for each treatment versus placebo comparison at each visit and use an analysis of covariance (ANCOVA) model including baseline as a covariate and treatment as fixed effect in the model.
Time frame: Baseline, 12 Weeks
Change From Baseline in Pain Visual Analog Scale (VAS) at Week 12
The pain VAS is a participant-administered single-item scale designed to measure current joint pain from psoriatic arthritis (PsA) using a 100- millimeter (mm) horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by placing a single mark on the horizontal 100-mm scale from 0mm (no pain) to 100 mm (pain as severe as you can imagine). A mixed effects model for repeated measures analysis was used. Least Squares (LS) Mean values were calculated using MMRM and were controlled for baseline as a covariate, visit, treatment and visit by treatment interaction as fixed effects, with variance-covariance structure set to unstructured.
Time frame: Baseline, Week 12
Change From Baseline in Medical Outcomes Study Sleep Scale (MOS-S) at Week 16
MOS-S provides a concise assessment of important dimensions of sleep, including initiation, maintenance, respiratory problems, quantity, perceived adequacy, and somnolence during the past 4 weeks. Scoring based on 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100,with higher scores for more impairment); sleep quantity (range:0-24), and optimal sleep (yes:1, no:0). Six(6) and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = higher scores indicate greater problems with the attribute.The LS Mean (no multiplicity adjustments) was calculated using an analysis of covariance (ANCOVA) model including baseline as a covariate and treatment as fixed effect in the model.
Time frame: Baseline, Week 16
Number of Participants Who Received Medical Care Measured by Medical Care Resource Utilization (PMRU))
The PMRU is a 3-item participant-reported questionnaire on health care resource utilization due to psoriasis for physician/clinic visits, emergency room visits, and inpatient hospital admissions since the last study visit.
Time frame: Week 16
Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI Q) at Week 16
The WPAI questionnaire has six questions to assess whether the participant was currently employed (Q1); how many hours from work were missed due to problems associated with psoriasis (Q2) or any other reason (Q3); hours actually worked (Q4); degree that psoriasis affected productivity while working (Q5); and degree that psoriasis affected regular activities (Q6) over the past 7 days. Four separate overall scores were calculated, Absenteeism (work time missed) = (Q2/(Q2+Q4))\*100, Presenteeism(impairment at work/reduced on-the-job effectiveness) = (Q5/10) \*100, Work productivity loss(overall work impairment /absenteeism plus presenteeism) = (Q2/(Q2+Q4)+\[(1-Q2/(Q2+Q4))x(Q5/10)\]) \* 100 and Activity Impairment = (Q6/10) \* 100. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity ( worse outcomes). The LS Mean was calculated using ANCOVA model including baseline as a covariate and treatment as fixed effect in the model.
Time frame: Baseline, Week 16
Change From Baseline in Medical Outcomes Study Short-Form 36 (SF-36) - Physical Component Score (PCS) and Mental Component Score (MCS) at Week 16
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. The recall period was the past 4 weeks. The LS Mean was calculated using ANCOVA model including baseline as a covariate and treatment as fixed effect in the model.
Time frame: Baseline, Week 16
Change From Baseline in Nail Psoriasis Severity Index (NAPSI) in Participants With Nail Psoriasis at Week 12
The NAPSI is physician-rated and quantifies the severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix and nail bed. Each finger nail is divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). Participant's fingers and toes were evaluated and the sum of the scores was added resulting in a range of 0 to 160; higher scores indicate greater severity. If an individual toe or finger assessment was missing (not done), the average of the remaining measured digits was imputed and added to the sum. If \<50% of the toes or finger assessments were missing, the imputation was performed. If \>50% of the assessments were missing, then the sum of the scores was left as missing. LS mean was calculated using MMRM with baseline score as covariate, visit, treatment and visit by treatment interaction as fixed effects.
Time frame: Baseline, Week 12
Change From Baseline in Palmoplantar Psoriasis Severity Index (PPASI) in Participants With Palmoplantar Psoriasis at Week 12
The PPASI is a physician-assessed composite score derived from the summed scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement. The PPASI score ranges from 0 to 72, with higher scores representing greater severity of palmoplantar psoriasis.LS mean was calculated using MMRM with baseline score as covariate, visit, treatment and visit by treatment interaction as fixed effects, with variance-covariance structure set to symmetric.
Time frame: Baseline, Week 12
Change From Baseline in Scalp Psoriasis Severity Index (PSSI) in Participants With Scalp Psoriasis at Week 12
The PSSI is a physician-assessed composite score derived from the summed scores for erythema, induration, and desquamation multiplied by a score for the extent of scalp area involved. The PSSI score ranges from 0 to 72, with higher scores representing greater severity of scalp psoriasis.LS mean was calculated using MMRM with baseline score as covariate, visit, treatment and visit by treatment interaction as fixed effects, with variance-covariance structure set to unstructured.
Time frame: Baseline, Week 12
Ixekizumab Systemic Clearance (CL) (Serum Concentrations of Ixekizumab From Baseline Through 32 Weeks)
The population pharmacokinetic (PK) modeling value for systemic clearance was based on data from week 1 to week 32 for all participants in all ixekizumab treatment arms.
Time frame: Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28 and Week 32
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score Total Score at Week 16
The DLQI is a 10-item, participant-administered dermatology-specific questionnaire that assess health related quality of life that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The DLQI items response categories are scored 0 (not relevant) to 3 (very much) with a total score range of 0 to 30; higher scores indicate poor quality of life and a 5-point change from baseline is considered clinically relevant. The LS Mean(no multiplicity adjustments) are presented for each treatment versus placebo comparison at each visit and use an analysis of covariance (ANCOVA) model including baseline as a covariate and treatment as fixed effect in the model.
Time frame: Baseline, Week 16
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12
PASI combines the extent of body surface involvement in 4 anatomical regions(head,trunk,arms,and legs).For each region the percent area of skin involved was estimated from 0(0%) to 6(90%-100%) and severity was estimated by clinical signs of erythema,induration and scaling with a scores range from 0(none) to 4(very severe).Each area is scored by itself and the scores were then combined for the final PASI.Final PASI calculated as:sum of severity parameters for each region\*area score\*weighing factor (head\[0.1\],upper limbs\[0.2\],trunk\[0.3\],lower limbs \[0.4\]).Overall scores range from 0(no psoriasis) to 72(most severe disease).The LS mean are presented for each treatment versus placebo comparison at each visit and use ANCOVA model including baseline PASI covariate and treatment as fixed effect in the model.Results at Week 12 are summarized as Improvement in PASI which is defined as a reduction in the PASI calculated score at a visit as compared to the score calculated at the baseline visit.
Time frame: Baseline, Week 12
Percentage of Participants Who Achieve a 75% Improvement in the Psoriasis Area and Severity Index (PASI 75)
PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no psoriasis) to 72 (the most severe disease). Participants achieving PASI 75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.
Time frame: Week 32
Percentage of PASI Improvement From Baseline Through 32 Weeks
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no psoriasis) to 72 (the most severe disease). Improvement in PASI is defined as improvement in the PASI calculated score at a visit as compared to the score calculated at the baseline visit.
Time frame: Baseline Through 32 Weeks
Percentage of Participants With a Static Physician's Global Assessment (sPGA) Score of Cleared (0) or Minimal (1) With at Least a 2 Point Improvement
The sPGA of psoriasis is scored on a 6-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 6-point severity scale (0 \[clear\] to 5 \[severe\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the sPGA score and category (0=clear; 1=minimal; 2=mild; 3=moderate; 4=marked; 5 = severe). As defined by protocol, a responder is a participant who has a post-baseline sPGA score of '0' or a post-baseline score of '1' with at least a 2 point improvement from baseline.
Time frame: Week 32
Percentage of Participants With Anti-Ixekizumab Antibodies
Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.
Time frame: Baseline through Week 20
Percentage of Participants With Static Physician's Global Assessment (sPGA) of (0,1)
The sPGA of psoriasis is scored on a 6-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 6-point severity scale (0 \[clear\] to 5 \[severe\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the sPGA score and category (0=clear; 1=minimal; 2=mild; 3=moderate; 4=marked; 5 = severe). As defined by protocol, a responder is a participant who has a post-baseline sPGA score of '0' or a post-baseline score of '1' with at least a 2 point improvement from baseline.
Time frame: Baseline Up to 240 Weeks
Number of Treatment Emergent Adverse Events up to 344 Weeks
Treatment-emergent adverse events (TEAEs) are events which were not present at baseline or pre-existing conditions at baseline that worsened in severity following the start of treatment. A summary of other non-serious Adverse Events (AEs), and all Serious Adverse Events (SAE's), regardless of causality, is located in the Reported Adverse Events section.
Time frame: Baseline Up to 344 Weeks
Change From Baseline in Hospital Anxiety and Depression Scale (HADS)
The HADS is a 14-item, participant self-reported scale that consists of an anxiety scale and a depression scale, each with 7 items. Items are rated on a 4-point Likert-type scale ranging from 0 (low level of anxiety or depression) to 3 (high level of anxiety or depression). Each subscale score ranges from 0 to 21 with higher scores indicating greater symptom severity. The classification is defined: 0-7 normal, 8-10 Borderline, 11-21 Abnormal.
Time frame: Baseline Up to 240 Weeks
Number of Participants With Patient's Global Assessment of Disease Activity (PatGA)
The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis "today" by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been).
Time frame: Week 240
Change From Baseline in Pain Visual Analog Scale (VAS)
The pain VAS is a participant-administered single-item scale designed to measure current joint pain from psoriatic arthritis (PsA) using a 100- millimeter (mm) horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by placing a single mark on the horizontal 100-mm scale from 0mm (no pain) to 100 mm (pain as severe as you can imagine). A mixed effects model for repeated measures analysis was used.
Time frame: Baseline Up to 240 Weeks
Change From Baseline up to 240 Weeks in Nail Psoriasis Severity Index (NAPSI) in Participants With Nail Psoriasis
The NAPSI is physician-rated and quantifies the severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix and nail bed. Each finger nail is divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). Participant's fingers and toes were evaluated and the sum of the scores was added resulting in a range of 0 to 160; higher scores indicate greater severity. If an individual toe or finger assessment was missing (not done), the average of the remaining measured digits was imputed and added to the sum. If \<50% of the toes or finger assessments were missing, the imputation was performed. If \>50% of the assessments were missing, then the sum of the scores was left as missing. Baseline is defined as the last available value prior to the first dose in Part A of the study.
Time frame: Baseline Up to 240 Weeks
Change From Baseline up to 240 Weeks in Scalp Psoriasis Severity Index (PSSI) in Participants With Scalp Psoriasis
The PSSI is a physician-assessed composite score derived from the summed scores for erythema, induration, and desquamation multiplied by a score for the extent of scalp area involved. The PSSI score ranges from 0 to 72, with higher scores representing greater severity of scalp psoriasis. Baseline is defined as the last available value prior to the first dose in Part A of the study.
Time frame: Baseline Up to 240 Weeks
Change From Baseline up to 240 Weeks in Palmoplantar Psoriasis Severity Index (PPASI) in Participants With Palmoplantar Psoriasis
The PPASI is a physician-assessed composite score derived from the summed scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement. The PPASI score ranges from 0 to 72, with higher scores representing greater severity of palmoplantar psoriasis.LS mean was calculated using MMRM with baseline score as covariate, visit, treatment and visit by treatment interaction as fixed effects, with variance-covariance structure set to symmetric.
Time frame: Baseline Up to 240 Weeks
Percentage of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement
PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no psoriasis) to 72 (the most severe disease).Participants achieving PASI 75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.
Time frame: Week 240
Change From Baseline in Dermatology Life Quality Index (DLQI)
The DLQI is a 10-item, participant-administered dermatology-specific questionnaire that assess health related quality of life that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The DLQI items response categories are scored 0 (not relevant) to 3 (very much) with a total score range of 0 to 30; higher scores indicate poor quality of life and a 5-point change from baseline is considered clinically relevant. Baseline is defined as the last available value prior to the first dose in Part A of the study.
Time frame: Baseline Up to 240 Weeks
This study has 3 parts:Part A is a randomized, double-blind, placebo-controlled, parallel-group, dose ranging design (approximately 20-40 weeks \[wks\]).Treatment durability (sustained efficacy off treatment) from Week 20 up to Week 32 was evaluated during Part A.
| Milestone | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab | 120 mg/80 mg Total Ixekizumab |
|---|---|---|---|---|---|---|
| Started | 27 | 28 | 30 | 29 | 28 | 0 |
| Received at least 1 dose of study drug | 27 | 28 | 30 | 29 | 28 | 0 |
| Completed | 22 | 21 | 29 | 26 | 27 | 0 |
| Not completed | 5 | 7 | 1 | 3 | 1 | 0 |
| Withdrew: Adverse event | 1 | 2 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 3 | 0 | 3 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab | 120 mg/80 mg Total Ixekizumab |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 120 |
| Completed part b (week 240) | 0 | 0 | 0 | 0 | 0 | 74 |
| Completed part c | 0 | 0 | 0 | 0 | 0 | 0 |
| Post treatment safety visits | 0 | 0 | 0 | 0 | 0 | 6 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 120 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 12 |
| Withdrew: Inclusion/exclusion criteria not met | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 7 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 10 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 0 | 66 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 16 |
| Withdrew: Clinical relapse | 0 | 0 | 0 | 0 | 0 | 4 |
PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no psoriasis) to 72 (the most severe disease).Participants achieving PASI 75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.
| percentage of participants | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab |
|---|---|---|---|---|---|
| Percentage of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement | 7.7 | 28.6 | 76.7 | 82.8 | 82.1 |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no psoriasis) to 72 (the most severe disease). Least squares (LS) mean values were calculated using mixed model repeated measures (MMRM) and controlled for baseline as a covariate, visit, treatment and visit by treatment interaction as fixed effects, with variance-covariance structure set to unstructured.
| Percentage of improvement in PASI score | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab |
|---|---|---|---|---|---|
| Percentage of PASI Improvement From Baseline to 12 Week Endpoint | 16.22 (4.44 to 28.01) | 49.33 (38.25 to 60.41) | 78.48 (67.67 to 89.29) | 85.69 (74.87 to 96.50) | 87.12 (75.94 to 98.29) |
The sPGA of psoriasis is scored on a 6-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 6 point severity scale (0 \[clear\] to 5 \[severe\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the sPGA score and category (0=clear; 1=minimal; 2=mild; 3=moderate; 4=marked; 5 = severe). As defined by protocol, a responder is a participant who has a post-baseline sPGA score of '0' or a post-baseline score of '1' with at least a 2 point improvement from baseline.
| percentage of participants | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab |
|---|---|---|---|---|---|
| Percentage of Participants With a Static Physician's Global Assessment (sPGA) Score of Cleared (0) or Minimal (1) With at Least a 2 Point Improvement" at Week 12 | 7.7 | 25.0 | 70.0 | 72.4 | 71.4 |
Treatment-emergent adverse events (TEAEs) are events which were not present at baseline or pre-existing conditions at baseline that worsened in severity following the start of treatment. A summary of other non-serious Adverse Events (AEs), and all Serious Adverse Events (SAE's), regardless of causality, is located in the Reported Adverse Events section.
| Participants | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab |
|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events Up to 20 Weeks | 17 | 21 | 21 | 17 | 13 |
The HADS is a 14-item, participant self-reported scale that consists of an anxiety scale and a depression scale, each with 7 items. Items are rated on a 4-point Likert-type scale ranging from 0 (low level of anxiety or depression) to 3 (high level of anxiety or depression). Each subscale score ranges from 0 to 21 with higher scores indicating greater symptom severity. The classification is defined: 0-7 normal, 8-10 Borderline, 11-21 Abnormal. LS mean was calculated using the analysis of covariance (ANCOVA) model including treatment as fixed effect and baseline as covariate.
| units on a scale | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab |
|---|---|---|---|---|---|
| Anxiety | -0.86 ± 0.58 | -1.97 ± 0.55 | -2.10 ± 0.54 | -2.17 ± 0.54 | -2.81 ± 0.55 |
| Depression | 0.17 ± 0.54 | -1.86 ± 0.51 | -1.75 ± 0.51 | -2.52 ± 0.51 | -2.01 ± 0.51 |
The QIDS-SR16 is a self-administered, 16-item instrument in which a participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 (best) to 3 (worst). The 16 items are scored to give 9 individual depression domains (sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance \[initial, middle and late insomnia or hypersomnia\], decrease/increase in appetite/weight, and psychomotor agitation/retardation), which are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. The LS Mean (no multiplicity adjustments) are presented for each treatment versus placebo comparison at each visit and use an analysis of covariance (ANCOVA) model including baseline as a covariate and treatment as fixed effect in the model.
| units on a scale | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab |
|---|---|---|---|---|---|
| Change From Baseline in 16-Item Quick Inventory of Depressive Symptoms- Self Rated (QIDS-SR16) Total Score at Week 16 | -0.49 ± 0.56 | -1.56 ± 0.52 | -1.48 ± 0.53 | -2.13 ± 0.52 | -2.21 ± 0.54 |
The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis "today" by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been). The LS Mean (no multiplicity adjustments) are presented for each treatment versus placebo comparison at each visit and use an analysis of covariance (ANCOVA) model including baseline as a covariate and treatment as fixed effect in the model.
| units on a scale | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab |
|---|---|---|---|---|---|
| Change From Baseline in Patient Global Assessment (PatGA) at Week 12 | -0.6 ± 0.3 | -1.1 ± 0.3 | -2.3 ± 0.2 | -2.9 ± 0.3 | -2.5 ± 0.3 |
The pain VAS is a participant-administered single-item scale designed to measure current joint pain from psoriatic arthritis (PsA) using a 100- millimeter (mm) horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by placing a single mark on the horizontal 100-mm scale from 0mm (no pain) to 100 mm (pain as severe as you can imagine). A mixed effects model for repeated measures analysis was used. Least Squares (LS) Mean values were calculated using MMRM and were controlled for baseline as a covariate, visit, treatment and visit by treatment interaction as fixed effects, with variance-covariance structure set to unstructured.
| millimeter (mm) | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab |
|---|---|---|---|---|---|
| Change From Baseline in Pain Visual Analog Scale (VAS) at Week 12 | 3.87 (-20.90 to 28.64) | -4.32 (-23.05 to 14.41) | -19.36 (-34.31 to -4.40) | -21.24 (-37.89 to -4.58) | -34.24 (-51.83 to -16.66) |
MOS-S provides a concise assessment of important dimensions of sleep, including initiation, maintenance, respiratory problems, quantity, perceived adequacy, and somnolence during the past 4 weeks. Scoring based on 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100,with higher scores for more impairment); sleep quantity (range:0-24), and optimal sleep (yes:1, no:0). Six(6) and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = higher scores indicate greater problems with the attribute.The LS Mean (no multiplicity adjustments) was calculated using an analysis of covariance (ANCOVA) model including baseline as a covariate and treatment as fixed effect in the model.
| units on a scale | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab |
|---|---|---|---|---|---|
| Sleep Problems Index I | -0.05 ± 2.61 | -5.35 ± 2.46 | -8.78 ± 2.42 | -7.97 ± 2.42 | -2.38 ± 2.47 |
| Sleep Problems Index II | 0.21 ± 2.37 | -6.42 ± 2.24 | -9.23 ± 2.20 | -8.43 ± 2.20 | -2.48 ± 2.24 |
| Sleep Adequacy | -2.83 ± 4.73 | 5.63 ± 4.47 | 11.35 ± 4.39 | 8.81 ± 4.39 | -0.41 ± 4.48 |
| Sleep Disturbance | -1.47 ± 3.27 | -8.56 ± 3.10 | -10.02 ± 3.03 | -11.50 ± 3.04 | -4.67 ± 3.09 |
| Sleep Somnolence | 1.12 ± 2.73 | -2.32 ± 2.58 | -7.14 ± 2.53 | -5.80 ± 2.53 | -0.76 ± 2.58 |
| Snoring | -2.85 ± 4.22 | -0.47 ± 3.94 | 2.94 ± 3.88 | -3.24 ± 3.87 | -3.81 ± 3.94 |
| Sleep Short of Breath/headache | 4.34 ± 3.10 | -5.45 ± 2.92 | -2.84 ± 2.87 | -2.65 ± 2.87 | -3.46 ± 2.91 |
The PMRU is a 3-item participant-reported questionnaire on health care resource utilization due to psoriasis for physician/clinic visits, emergency room visits, and inpatient hospital admissions since the last study visit.
| participants | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab |
|---|---|---|---|---|---|
| Week 16 - Office or Clinic(n=23,24,29,28,27) | 1 | 0 | 0 | 1 | 3 |
| Week 16 - Emergency Room(ER)(n=23, 24, 29, 28, 27) | 0 | 0 | 0 | 0 | 1 |
| Week 16 - Admitted thru ER (n=26,28,30,29,28) | 0 | 0 | 0 | 0 | 0 |
| Week 16 - Hospital Stay (n=26,28,30,29,28) | 0 | 0 | 0 | 0 | 0 |
The WPAI questionnaire has six questions to assess whether the participant was currently employed (Q1); how many hours from work were missed due to problems associated with psoriasis (Q2) or any other reason (Q3); hours actually worked (Q4); degree that psoriasis affected productivity while working (Q5); and degree that psoriasis affected regular activities (Q6) over the past 7 days. Four separate overall scores were calculated, Absenteeism (work time missed) = (Q2/(Q2+Q4))\*100, Presenteeism(impairment at work/reduced on-the-job effectiveness) = (Q5/10) \*100, Work productivity loss(overall work impairment /absenteeism plus presenteeism) = (Q2/(Q2+Q4)+\[(1-Q2/(Q2+Q4))x(Q5/10)\]) \* 100 and Activity Impairment = (Q6/10) \* 100. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity ( worse outcomes). The LS Mean was calculated using ANCOVA model including baseline as a covariate and treatment as fixed effect in the model.
| units on a scale | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab |
|---|---|---|---|---|---|
| Absenteeism (n=15,19,14,19,16) | -1.91 ± 1.88 | 0.71 ± 1.68 | -0.83 ± 1.94 | -2.64 ± 1.67 | -1.96 ± 1.82 |
| Presenteeism (n=15,20,16,19,16) | -3.38 ± 3.99 | -0.99 ± 3.47 | -4.59 ± 3.87 | -14.48 ± 3.55 | -10.69 ± 3.90 |
| Work productivity loss (n=15,19,14,19,16) | -3.65 ± 4.30 | 1.74 ± 3.82 | -4.65 ± 4.45 | -14.76 ± 3.82 | -11.12 ± 4.17 |
| Activity Impairment (n=25,28,28,29,27) | -0.68 ± 4.19 | -9.76 ± 3.96 | -14.96 ± 3.95 | -12.81 ± 3.90 | -14.79 ± 4.03 |
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. The recall period was the past 4 weeks. The LS Mean was calculated using ANCOVA model including baseline as a covariate and treatment as fixed effect in the model.
| units on a scale | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab |
|---|---|---|---|---|---|
| PCS | -1.22 ± 2.15 | 2.41 ± 2.03 | 1.95 ± 2.03 | 3.94 ± 2.00 | 5.72 ± 2.03 |
| MCS | -0.56 ± 2.29 | 7.27 ± 2.19 | 5.16 ± 2.18 | 4.13 ± 2.13 | 4.15 ± 2.16 |
The NAPSI is physician-rated and quantifies the severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix and nail bed. Each finger nail is divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). Participant's fingers and toes were evaluated and the sum of the scores was added resulting in a range of 0 to 160; higher scores indicate greater severity. If an individual toe or finger assessment was missing (not done), the average of the remaining measured digits was imputed and added to the sum. If \<50% of the toes or finger assessments were missing, the imputation was performed. If \>50% of the assessments were missing, then the sum of the scores was left as missing. LS mean was calculated using MMRM with baseline score as covariate, visit, treatment and visit by treatment interaction as fixed effects.
| units on a scale | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab |
|---|---|---|---|---|---|
| Change From Baseline in Nail Psoriasis Severity Index (NAPSI) in Participants With Nail Psoriasis at Week 12 | 2.21 (-5.17 to 9.58) | -4.85 (-12.82 to 3.12) | -3.65 (-12.73 to 5.43) | -15.89 (-24.98 to -6.81) | -19.91 (-29.00 to -10.83) |
The PPASI is a physician-assessed composite score derived from the summed scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement. The PPASI score ranges from 0 to 72, with higher scores representing greater severity of palmoplantar psoriasis.LS mean was calculated using MMRM with baseline score as covariate, visit, treatment and visit by treatment interaction as fixed effects, with variance-covariance structure set to symmetric.
| units on a scale | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab |
|---|---|---|---|---|---|
| Change From Baseline in Palmoplantar Psoriasis Severity Index (PPASI) in Participants With Palmoplantar Psoriasis at Week 12 | -1.0 (-10.3 to 8.3) | -6.4 (-12.3 to -0.5) | -4.6 (-10.3 to 1.2) | -3.4 (-11.5 to 4.8) | -12.8 (-20.9 to -4.7) |
The PSSI is a physician-assessed composite score derived from the summed scores for erythema, induration, and desquamation multiplied by a score for the extent of scalp area involved. The PSSI score ranges from 0 to 72, with higher scores representing greater severity of scalp psoriasis.LS mean was calculated using MMRM with baseline score as covariate, visit, treatment and visit by treatment interaction as fixed effects, with variance-covariance structure set to unstructured.
| units on a scale | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab |
|---|---|---|---|---|---|
| Change From Baseline in Scalp Psoriasis Severity Index (PSSI) in Participants With Scalp Psoriasis at Week 12 | -7.3 (-11.2 to -3.5) | -10.2 (-13.9 to -6.6) | -15.8 (-19.2 to -12.4) | -15.0 (-18.9 to -11.0) | -17.2 (-20.8 to -13.7) |
The population pharmacokinetic (PK) modeling value for systemic clearance was based on data from week 1 to week 32 for all participants in all ixekizumab treatment arms.
| liters per hour (L/hr) | All Participants (10mg, 25mg,75mg & 150 mg Ixekizumab) |
|---|---|
| Ixekizumab Systemic Clearance (CL) (Serum Concentrations of Ixekizumab From Baseline Through 32 Weeks) | 0.0177 (0.0160 to 0.0199) |
The DLQI is a 10-item, participant-administered dermatology-specific questionnaire that assess health related quality of life that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The DLQI items response categories are scored 0 (not relevant) to 3 (very much) with a total score range of 0 to 30; higher scores indicate poor quality of life and a 5-point change from baseline is considered clinically relevant. The LS Mean(no multiplicity adjustments) are presented for each treatment versus placebo comparison at each visit and use an analysis of covariance (ANCOVA) model including baseline as a covariate and treatment as fixed effect in the model.
| units on a scale | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab |
|---|---|---|---|---|---|
| Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score Total Score at Week 16 | -1.24 ± 0.97 | -6.35 ± 0.92 | -6.59 ± 0.90 | -8.39 ± 0.90 | -8.17 ± 0.92 |
PASI combines the extent of body surface involvement in 4 anatomical regions(head,trunk,arms,and legs).For each region the percent area of skin involved was estimated from 0(0%) to 6(90%-100%) and severity was estimated by clinical signs of erythema,induration and scaling with a scores range from 0(none) to 4(very severe).Each area is scored by itself and the scores were then combined for the final PASI.Final PASI calculated as:sum of severity parameters for each region\*area score\*weighing factor (head\[0.1\],upper limbs\[0.2\],trunk\[0.3\],lower limbs \[0.4\]).Overall scores range from 0(no psoriasis) to 72(most severe disease).The LS mean are presented for each treatment versus placebo comparison at each visit and use ANCOVA model including baseline PASI covariate and treatment as fixed effect in the model.Results at Week 12 are summarized as Improvement in PASI which is defined as a reduction in the PASI calculated score at a visit as compared to the score calculated at the baseline visit.
| units on a scale | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab |
|---|---|---|---|---|---|
| Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12 | 3.50 ± 1.21 | 8.20 ± 1.17 | 13.56 ± 1.12 | 14.99 ± 1.14 | 15.38 ± 1.16 |
PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no psoriasis) to 72 (the most severe disease). Participants achieving PASI 75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.
| percentage of participants | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab |
|---|---|---|---|---|---|
| Percentage of Participants Who Achieve a 75% Improvement in the Psoriasis Area and Severity Index (PASI 75) | 0 | 50.0 | 59.1 | 56.5 | 82.6 |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no psoriasis) to 72 (the most severe disease). Improvement in PASI is defined as improvement in the PASI calculated score at a visit as compared to the score calculated at the baseline visit.
| Percentage PASI improvement | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab |
|---|---|---|---|---|---|
| Percentage of PASI Improvement From Baseline Through 32 Weeks | — | 80.55 ± 17.69 | 85.60 ± 12.74 | 85.16 ± 15.30 | 88.11 ± 11.35 |
The sPGA of psoriasis is scored on a 6-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 6-point severity scale (0 \[clear\] to 5 \[severe\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the sPGA score and category (0=clear; 1=minimal; 2=mild; 3=moderate; 4=marked; 5 = severe). As defined by protocol, a responder is a participant who has a post-baseline sPGA score of '0' or a post-baseline score of '1' with at least a 2 point improvement from baseline.
| percentage of participants | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab |
|---|---|---|---|---|---|
| Percentage of Participants With a Static Physician's Global Assessment (sPGA) Score of Cleared (0) or Minimal (1) With at Least a 2 Point Improvement | — | 33.3 | 45.5 | 47.8 | 65.2 |
Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.
| percentage of participants | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab |
|---|---|---|---|---|---|
| Percentage of Participants With Anti-Ixekizumab Antibodies | 4.0 | 54.2 | 40.0 | 17.2 | 22.2 |
The sPGA of psoriasis is scored on a 6-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 6-point severity scale (0 \[clear\] to 5 \[severe\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the sPGA score and category (0=clear; 1=minimal; 2=mild; 3=moderate; 4=marked; 5 = severe). As defined by protocol, a responder is a participant who has a post-baseline sPGA score of '0' or a post-baseline score of '1' with at least a 2 point improvement from baseline.
| percentage of participants | Total Ixekizumab (80 mg and 120 mg) |
|---|---|
| Percentage of Participants With Static Physician's Global Assessment (sPGA) of (0,1) | 78.4 |
Treatment-emergent adverse events (TEAEs) are events which were not present at baseline or pre-existing conditions at baseline that worsened in severity following the start of treatment. A summary of other non-serious Adverse Events (AEs), and all Serious Adverse Events (SAE's), regardless of causality, is located in the Reported Adverse Events section.
| Participants | Total Ixekizumab (80 mg and 120 mg) |
|---|---|
| Number of Treatment Emergent Adverse Events up to 344 Weeks | 105 |
The HADS is a 14-item, participant self-reported scale that consists of an anxiety scale and a depression scale, each with 7 items. Items are rated on a 4-point Likert-type scale ranging from 0 (low level of anxiety or depression) to 3 (high level of anxiety or depression). Each subscale score ranges from 0 to 21 with higher scores indicating greater symptom severity. The classification is defined: 0-7 normal, 8-10 Borderline, 11-21 Abnormal.
| units on a scale | Total Ixekizumab (80 mg and 120 mg) |
|---|---|
| Anxiety | -3.0 ± 3.4 |
| Depression | -2.8 ± 3.0 |
The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis "today" by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been).
| Participants | Total Ixekizumab (80 mg and 120 mg) |
|---|---|
| 0(Clear) | 40 |
| 1 | 26 |
| 2 | 4 |
| 3 | 2 |
| 4 | 2 |
| 5(Severe) | 0 |
The pain VAS is a participant-administered single-item scale designed to measure current joint pain from psoriatic arthritis (PsA) using a 100- millimeter (mm) horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by placing a single mark on the horizontal 100-mm scale from 0mm (no pain) to 100 mm (pain as severe as you can imagine). A mixed effects model for repeated measures analysis was used.
| Millimeters (mm) | Total Ixekizumab (80 mg and 120 mg) |
|---|---|
| Change From Baseline in Pain Visual Analog Scale (VAS) | -13.25 ± 32.34 |
The NAPSI is physician-rated and quantifies the severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix and nail bed. Each finger nail is divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). Participant's fingers and toes were evaluated and the sum of the scores was added resulting in a range of 0 to 160; higher scores indicate greater severity. If an individual toe or finger assessment was missing (not done), the average of the remaining measured digits was imputed and added to the sum. If \<50% of the toes or finger assessments were missing, the imputation was performed. If \>50% of the assessments were missing, then the sum of the scores was left as missing. Baseline is defined as the last available value prior to the first dose in Part A of the study.
| units on a scale | Total Ixekizumab (80 mg and 120 mg) |
|---|---|
| Change From Baseline up to 240 Weeks in Nail Psoriasis Severity Index (NAPSI) in Participants With Nail Psoriasis | -33.62 ± 30.48 |
The PSSI is a physician-assessed composite score derived from the summed scores for erythema, induration, and desquamation multiplied by a score for the extent of scalp area involved. The PSSI score ranges from 0 to 72, with higher scores representing greater severity of scalp psoriasis. Baseline is defined as the last available value prior to the first dose in Part A of the study.
| units on a scale | Total Ixekizumab (80 mg and 120 mg) |
|---|---|
| Change From Baseline up to 240 Weeks in Scalp Psoriasis Severity Index (PSSI) in Participants With Scalp Psoriasis | -19.89 ± 13.68 |
The PPASI is a physician-assessed composite score derived from the summed scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement. The PPASI score ranges from 0 to 72, with higher scores representing greater severity of palmoplantar psoriasis.LS mean was calculated using MMRM with baseline score as covariate, visit, treatment and visit by treatment interaction as fixed effects, with variance-covariance structure set to symmetric.
| units on a scale | Total Ixekizumab (80 mg and 120 mg) |
|---|---|
| Change From Baseline up to 240 Weeks in Palmoplantar Psoriasis Severity Index (PPASI) in Participants With Palmoplantar Psoriasis | -9.10 ± 7.59 |
PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no psoriasis) to 72 (the most severe disease).Participants achieving PASI 75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.
| percentage of participants | Total Ixekizumab (80 mg and 120 mg) |
|---|---|
| Percentage of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement | 97.3 |
The DLQI is a 10-item, participant-administered dermatology-specific questionnaire that assess health related quality of life that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The DLQI items response categories are scored 0 (not relevant) to 3 (very much) with a total score range of 0 to 30; higher scores indicate poor quality of life and a 5-point change from baseline is considered clinically relevant. Baseline is defined as the last available value prior to the first dose in Part A of the study.
| units on a scale | Total Ixekizumab (80 mg and 120 mg) |
|---|---|
| Change From Baseline in Dermatology Life Quality Index (DLQI) | -9.2 ± 5.6 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/27 (3.7%) | 13/27 (48.1%) |
| 10 mg Ixekizumab | — | 1/28 (3.6%) | 15/28 (53.6%) |
| 25 mg Ixekizumab | — | 1/30 (3.3%) | 12/30 (40%) |
| 75 mg Ixekizumab | — | 0/29 (0%) | 10/29 (34.5%) |
| 150 mg Ixekizumab | — | 0/28 (0%) | 11/28 (39.3%) |
| Treatment Durability | — | 1/74 (1.4%) | 11/74 (14.9%) |
| 120 mg and 80 mg Total Ixekizumab | — | 24/120 (20%) | 82/120 (68.3%) |
| Post Treatment Safety Visits | — | 0/6 (0%) | 1/6 (16.7%) |
| Event | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab | Treatment Durability | 120 mg and 80 mg Total Ixekizumab | Post Treatment Safety Visits |
|---|---|---|---|---|---|---|---|---|
| DysmenorrhoeaReproductive system and breast disorders | 1/13 | 0/12 | 0/12 | 0/10 | 0/14 | 0/33 | 0/50 | 0/4 |
| Mitral valve prolapseCardiac disorders | 0/27 | 1/28 | 0/30 | 0/29 | 0/28 | 0/74 | 1/120 | 0/6 |
| NephrolithiasisRenal and urinary disorders | 0/27 | 0/28 | 1/30 | 0/29 | 0/28 | 1/74 | 2/120 | 0/6 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/13 | 0/12 | 0/12 | 0/10 | 0/14 | 0/33 | 1/50 | 0/4 |
| Abortion missedPregnancy, puerperium and perinatal conditions | 0/13 | 0/12 | 0/12 | 0/10 | 0/14 | 0/33 | 1/50 | 0/4 |
| Acute coronary syndromeCardiac disorders | 0/27 | 0/28 | 0/30 | 0/29 | 0/28 | 0/74 | 1/120 | 0/6 |
| Arteriosclerosis coronary arteryCardiac disorders | 0/27 | 0/28 | 0/30 | 0/29 | 0/28 | 0/74 | 1/120 | 0/6 |
| Atrial fibrillationCardiac disorders | 0/27 | 0/28 | 0/30 | 0/29 | 0/28 | 0/74 | 1/120 | 0/6 |
| Cardiac failure congestiveCardiac disorders | 0/27 | 0/28 | 0/30 | 0/29 | 0/28 | 0/74 | 1/120 | 0/6 |
| Pancreatitis acuteGastrointestinal disorders | 0/27 | 0/28 | 0/30 | 0/29 | 0/28 | 0/74 | 1/120 | 0/6 |
| Event | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab | Treatment Durability | 120 mg and 80 mg Total Ixekizumab | Post Treatment Safety Visits |
|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 5/27 | 3/28 | 3/30 | 3/29 | 4/28 | 2/74 | 29/120 | 0/6 |
| HypersensitivityImmune system disorders | 1/27 | 1/28 | 0/30 | 0/29 | 0/28 | 0/74 | 0/120 | 1/6 |
| HeadacheNervous system disorders | 1/27 | 4/28 | 4/30 | 1/29 | 1/28 | 3/74 | 12/120 | 0/6 |
| SinusitisInfections and infestations | 1/27 | 0/28 | 0/30 | 1/29 | 0/28 | 1/74 | 17/120 | 0/6 |
| Upper respiratory tract infectionInfections and infestations | 1/27 | 1/28 | 3/30 | 1/29 | 1/28 | 0/74 | 15/120 | 0/6 |
| Urinary tract infectionInfections and infestations | 0/27 | 1/28 | 1/30 | 0/29 | 1/28 | 2/74 | 13/120 | 0/6 |
| Injection site reactionGeneral disorders | 0/27 | 0/28 | 3/30 | 1/29 | 2/28 | 0/74 | 4/120 | 0/6 |
| Tooth infectionInfections and infestations | 0/27 | 1/28 | 0/30 | 1/29 | 0/28 | 0/74 | 11/120 | 0/6 |
| BronchitisInfections and infestations | 0/27 | 1/28 | 0/30 | 0/29 | 0/28 | 0/74 | 10/120 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 0/27 | 1/28 | 0/30 | 1/29 | 1/28 | 0/74 | 9/120 | 0/6 |
All randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab | Total |
|---|---|---|---|---|---|---|
| Mean | 45 ± 12.76 | 47.65 ± 11.20 | 45.93 ± 14.53 | 46.37 ± 12.50 | 45.97 ± 13.00 | 46.19 ± 12.71 |
| Sex: Female, Male(Participants) | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab | Total |
|---|---|---|---|---|---|---|
| Female | 13 | 12 | 12 | 10 | 14 | 61 |
| Male | 14 | 16 | 18 | 19 | 14 | 81 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 5 | 7 | 4 | 4 | 25 |
| Not Hispanic or Latino | 22 | 23 | 23 | 25 | 24 | 117 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 | 0 | 2 |
| Asian | 0 | 1 | 0 | 2 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 1 | 2 | 2 | 7 |
| White | 25 | 27 | 28 | 24 | 25 | 129 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab | Total |
|---|---|---|---|---|---|---|
| United States | 27 | 27 | 29 | 28 | 28 | 139 |
| Denmark | 0 | 1 | 1 | 1 | 0 | 3 |
| Baseline in Psoriasis Area and Severity Index (PASI)(units on a scale) | Placebo | 10 mg Ixekizumab | 25 mg Ixekizumab | 75 mg Ixekizumab | 150 mg Ixekizumab | Total |
|---|---|---|---|---|---|---|
| Mean | 16.45 ± 5.26 | 19.18 ± 7.96 | 18.55 ± 4.94 | 17.20 ± 4.26 | 17.70 ± 6.21 | 17.83 ± 5.85 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Apr 2010, a primary completion of Jan 2011 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2017, 6 years 6 months after primary completion. A results delay was requested in Apr 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab